Screener Summaries Updates Institutions Sign In More Updates › Other Events › SLN Other Events · Jun 11, 2026
Silence Therapeutics plc released follow-up and quality-of-life data from the Phase 1 SANRECO study of divesiran, an… SLN Silence Therapeutics plc
Silence Therapeutics plc released follow-up and quality-of-life data from the Phase 1 SANRECO study of divesiran, an siRNA therapy targeting TMPRSS6, in patients with polycythemia vera. The data was presented at the European Hematology Association (EHA) 2026 Annual Congress. Silence Therapeutics plc is a biotechnology company focused on developing siRNA therapies.
More from Silence Therapeutics plc Merck KGaA agrees to acquire Silence Therapeutics for $20.00 per ADS in all-cash deal Oct 19, 2026 Silence Therapeutics plc entered into an underwriting agreement on August 11, 2026, to sell 12,962,963 American… Aug 12, 2026 Silence Therapeutics plc announced positive topline results from the Phase 2 SANRECO trial of divesiran for… Aug 10, 2026 Silence Therapeutics plc reported financial results for the second quarter ended June 30, 2026 Aug 10, 2026 Silence Therapeutics plc entered into a separation and release agreement with former executive Craig Tooman, effective… Jul 16, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
